Filing Flows › Enanta Pharmaceuticals (ENTA) › Q2 FY26 › vs Q2 FY25
Enanta Pharmaceuticals (ENTA) Q2 FY26 vs Q2 FY25 (year over year)
Enanta Pharmaceuticals's revenue rose $2.2M (+15%) from $14.9M in Q2 FY25 to $17.2M in Q2 FY26.
Enanta Pharmaceuticals, Q2 FY26: revenue $17.2M (+15% year over year), operating margin -69.1%, net loss $13.1M, operating cash flow −$7.2M. The chart draws each line against Q2 FY25, the increases inside each band.
Every line
| Line | Q2 FY26 | Q2 FY25 | Change | % |
|---|---|---|---|---|
| Revenue | $17.2M | $14.9M | $2.2M | +15% |
| Net loss | $13.1M | $22.6M | −$9.6M | -42% |
| Costs & expenses | $30.2M | $39.5M | −$9.2M | -23% |
| Operating costs | $29.0M | $39.5M | −$10.4M | -26% |
| Interest & other, net | $1.2M | −$578K | $1.8M | — |
| Income tax | $7K | −$1.3M | $1.3M | — |
| Research & development | $19.4M | $28.1M | −$8.6M | -31% |
| General & admin | $9.6M | $11.4M | −$1.8M | -16% |
| Operating cash sources | $13.1M | $22.6M | −$9.6M | -42% |
| Depreciation & amortization | $1.2M | $1.2M | $6K | +0.5% |
| Share-based compensation | $3.7M | $4.7M | −$940K | -20% |
| Working capital & other | $978K | $3.3M | −$2.3M | -70% |
| Cash used in operations | $7.2M | $13.5M | −$6.3M | -47% |
| Net loss absorbed | $13.1M | $22.6M | −$9.6M | -42% |
Questions
How much did Enanta Pharmaceuticals's revenue grow year over year in Q2 FY26?
Enanta Pharmaceuticals's revenue rose $2.2M (+15%) from $14.9M in Q2 FY25 to $17.2M in Q2 FY26.